Mustang Bio (MBIO)
Develops a combined oncolytic-virus and CAR T treatment for recurrent brain tumors.
Something off on this page? Send us feedback.
Develops the MB-109 brain-cancer program, combining an oncolytic virus with IL13Rα2-directed CAR T cells through licenses and work with academic partners; it has no approved products or product revenue.
Develops MB-109, an experimental treatment program for recurrent glioblastoma and high-grade astrocytoma. The program combines MB-108, an oncolytic herpes virus intended to alter the tumor environment, with MB-101, autologous CAR T cells directed at IL13Rα2-positive tumors. Neither component has been tested clinically together, and there are no approved products or product revenue.
Works through a U.S.-centered network of academic institutions rather than a commercial operating footprint. City of Hope licenses and supports MB-101, while Nationwide Children's Hospital licenses MB-108; potential combination-study supply may also involve NIH manufacturing. Development depends on partner coordination, trial execution, manufacturing capacity, regulatory progress, and equity financing. Fortress Biotech retains voting control and related-party fee rights.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $15.2M · Total debt $0 · Total assets $15.6M · Shareholders' equity $7.5M
- Revenue
- $0
- Operating income
- −$1.2M
- Net income
- −$1.1M
No dividends on record.
| Institutions0 holders · as of Jun 30, 2026 · largest filers only | ≥ 1.50% | 113.7K shares | |
| Insiders4 holders · as of Apr 27, 2026 | 0.03% | 2.4K shares | |
| Strategic holders1 holder · as of Jan 5, 2026 | 7.09% | 537.2K shares | |
| Otherremainder | ≤ 91.38% | 6.92M shares |
7.58M company shares as of Sep 3, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This company has 2 share classes; every stake here is a share of the whole company.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Fortress Biotech, Inc.Strategic10 percent owner | 7.09% | 537,243 | 13Dfiled Jan 5, 2026 ↗ |
Geode Capital Management, LLCInstitution | 0.56% | 42,240 | 13Fas of Jun 30, 2026 |
Vanguard Fiduciary Trust CoInstitution | 0.42% | 32,120 | 13Fas of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 0.34% | 25,704 | 13Fas of Jun 30, 2026 |
Susquehanna International Group, LLPInstitution | 0.18% | 13,664 | 13Fas of Jun 30, 2026 |
| See all 16 → | |||
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Dec 30, 2025 | David Jin | director | +247 | $0.9620 |
| Dec 30, 2025 | Adam J. Chill | director | −4 | $0.9548 |
| Dec 30, 2025 | Neil Herskowitz | director | −247 | $0.9620 |
- Gilead Sciences
Dual-target CAR T trial targets recurrent glioblastoma.
- ImmunityBio
Active recurrent-GBM trial combines N-803, NK cells, and bevacizumab.
- Candel Therapeutics
CAN-3110 is an oncolytic HSV-1 trial in recurrent high-grade glioma.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Mustang Bio | $0.5473 | −0.15% | $4.1M | — | — | — | — |
| Gilead Sciences | $149.00 | −0.41% | $185.75B | — | 16.5 | 6.1 | +10.2% |
| ImmunityBio | $7.95 | −0.27% | $8.33B | — | — | 50.2 | +93.9% |
| Candel Therapeutics | $13.17 | +2.49% | $967.2M | — | — | — | — |
| Median | — | 16.5 | 28.2 | +52.1% |